MK-677 vs HGH — the complete comparison.
Ibutamoren vs injectable growth hormone — how they work differently at the receptor level, what the clinical data shows about relative efficacy, administration convenience, side effect profiles, cost, and which approach may be more appropriate for different clinical goals.
Mechanism: stimulation vs replacement
The fundamental difference between MK-677 and injectable HGH is the mechanism of action. MK-677 stimulates your pituitary gland to produce more of its own growth hormone by activating the ghrelin receptor (GHSR). Injectable HGH bypasses your pituitary entirely and delivers exogenous growth hormone directly into circulation.
This distinction has important implications:
- MK-677 preserves natural GH pulsatility — your GH is still released in pulses (especially during sleep), just with greater amplitude and frequency. This mimics natural physiology.
- Injectable HGH produces a single spike — after injection, GH levels spike to supraphysiological levels, then decline as the exogenous hormone is cleared. This is a non-physiological pattern.
- MK-677 does not cause pituitary shutdown — because it stimulates rather than replaces, your pituitary continues to function normally. Injectable HGH at sufficient doses can suppress endogenous GH production through negative feedback.
Efficacy comparison
| Outcome | MK-677 (25 mg/day) | Injectable HGH (1–2 IU/day) |
|---|---|---|
| GH increase | ~97% above baseline | Dose-dependent; can exceed 300% |
| IGF-1 increase | ~55% above baseline | ~100–200% above baseline |
| Lean mass gain | +1.6 kg over 12 months (elderly) | +2–4 kg over 6–12 months |
| Fat loss | Minimal direct effect | Moderate — especially visceral fat |
| Sleep improvement | +50% Stage IV sleep | Improved (but injection timing matters) |
| Bone density | Increased over 12–18 months | Increased over 12+ months |
Injectable HGH produces greater absolute GH and IGF-1 elevation than MK-677, particularly at higher doses. However, MK-677 achieves clinically meaningful effects through a simpler, oral route with fewer logistical requirements and lower cost.
Administration
This is where MK-677 has its clearest advantage. Injectable HGH requires daily subcutaneous injections, refrigerated storage, precise dose measurement, needle disposal, and injection site rotation. MK-677 is a single oral dose taken once daily — no needles, no refrigeration, no special storage. For patients who are needle-averse or who travel frequently, this is a significant practical benefit.
Side effect comparison
Both compounds share GH-related side effects (water retention, insulin sensitivity changes, joint pain, carpal tunnel-like symptoms) because both elevate GH. MK-677 uniquely causes appetite stimulation due to its ghrelin receptor mechanism. Injectable HGH uniquely carries the risk of pituitary suppression with long-term use and potential injection site reactions.
Who should consider each
- MK-677 may be more appropriate for: anti-aging, sleep optimization, general recovery enhancement, bone health, individuals seeking oral administration, cost-sensitive patients, those without diagnosed GH deficiency
- Injectable HGH may be more appropriate for: diagnosed GH deficiency requiring supraphysiological replacement, severe body composition goals, patients who need precise dose control, clinical settings with endocrinologist oversight